Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on November 9, 2023. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2023. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reported periods. Investors must refer to the attached press release (Exhibit 99.1) for these figures.
Material Changes
No specific material changes versus prior periods are detailed in this document. The filing solely references the issuance of the press release containing the comparative financial results.
Guidance, Outlook, and Risks
This document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It includes a standard legal disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the cash position and burn rate details not included in this summary text.
- Review the full text of the press release for any updated operational milestones or product development status.
- Note that the registrant is Oncocyte Corporation, not "Insight Molecular Diagnostics Inc." as indicated in the request metadata.